Paul Workman PhD DSc (Hon) FRS FMedSci FSB FRSC is the Chief Executive and President of The Institute of Cancer Research (ICR) in London UK which works in close partnership with the Royal Marsden Hospital and is a college of the University of London. Paul is also Harrap Professor of Pharmacology and Therapeutics and Director of the Cancer Research UK (CRUK) Centre at the ICR and Royal Marsden. From 1997 to 2016 he was Head of the ICR’s Division of Cancer Therapeutics and Director of the CRUK Cancer Therapeutics Unit – the world’s largest academic cancer drug discovery centre. Paul has been elected a Fellow of the Royal Society, Fellow of the Academy of Medical Sciences, Fellow of the Royal Society of Medicine, Fellow of the Society of Biology, Fellow of the Royal Society of Chemistry and Fellow of the European Academy of Cancer Sciences and he is CRUK Life Fellow. He was formerly Biology Section Head of Cancer Research, AstraZeneca Ltd. He was also the scientific founder of two oncology companies (Piramed Pharma, acquired by Roche, and Chroma Therapeutics) and has served as a consultant to many others. Paul has won a number of awards for his discovery and development of new cancer drugs, including protein kinase, PI3 kinase and HSP90 inhibitors. He is a Cancer Research UK Life Fellow and winner of the 2010 Royal Society of Chemistry George and Christine Sosnovsky Award for Cancer Therapy and the 2012 Royal Society of Chemistry World Entrepreneur of the Year Award. Paul is the leader of the teams that received the 2012 American Association of Cancer Research Team Science Award and the 2013 Cancer Research UK Translational Cancer Research Prize. In 2014 Paul received the international Raymond Bourgine Award for excellence in cancer research.